Table 1.
Clinical data from multiple sclerosis patients before and after autologous haematopoietic stem cell transplantation
| Controls gender/age (years) | Patients gender/age (years) | MS subtypes | Disease duration (years) | EDSS pre‐AHSCT | EDSS day + 180/ day + 360/day+ 720 post‐AHSCT | MRI pre‐AHSCT/post‐AHSCT | Previous therapy | Clinical response at day + 720 post‐AHSCT |
|---|---|---|---|---|---|---|---|---|
| M/37 | M/37 | SP | 14 | 6·5 | 6·5/6·5/6·0 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| M/48 | M/52 | SP | 09 | 6·5 | 6·0/6·0/7·5 | Inactivity/n.d. | STER/IFN/GA | Progression |
| M/52 | M/50 | SP | 09 | 6·5 | 8·0/7·5/7·5 | Inactivity/inactivity | STER/IFN/GA | Progression |
| F/42 | F/43 | SP | 12 | 6·5 | 8·0/7·5/7·5 | Inactivity/inactivity | STER/IFN/GA | Progression |
| F/42 | F/42 | SP | 11 | 7·0 | 7·0/9·0/9·0 | Inactivity/n.d. | STER/IFN/GA | Progression |
| M/20 | M/31 | PP | 04 | 6·5 | 6·5/6·5/6·5 | Activity/inactivity | STER/IFN/GA | Non‐progression |
| M/54 | M/52 | PP | 11 | 6·5 | 6·5/6·5/7·5 | Inactivity/n.d. | STER/IFN/GA | Progression |
| F/47 | F/44 | SP | 20 | 6·5 | 6·5/6·5/6·5 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| F/48 | F/48 | SP | 10 | 4·5 | 2·5/3·0/3·0 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| M/55 | M/54 | SP | 09 | 6·5 | 6·5/6·0/6·0 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| F/33 | F/36 | SP | 14 | 6·5 | 6·5/7·0/8·0 | Inactivity/inactivity | STER/IFN/GA | Progression |
| F/32 | F/32 | SP | 06 | 6·0 | 6·0/6·0/6·0 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| F/40 | F/42 | SP | 10 | 6·0 | 6·0/6·0/6·0 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| M/47 | M/49 | PP | 10 | 6·5 | 6·5/6·5/6·5 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| F/36 | F/38 | PP | 09 | 6·5 | 6·5/6·5/6·5 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| F/36 | F/36 | SP | 11 | 5·0 | 2·5/2·5/2·5 | Inactivity/inactivity | STER/IFN/GA | Non‐progression |
| M/33 | M/33 | SP | 11 | 6·5 | 6·5/6·5/7·0 | Activity/inactivity | STER/IFN/GA | Progression |
| F/30 | F/31 | SP | 06 | 6·5 | 5·5/5·0/4·5 | Activity/inactivity | STER/IFN/GA | Non‐progression |
M = male; F = female; MS = multiple sclerosis; SP = secondary progressive; PP = primary progressive; EDSS = expanded disability status scale; MRI = magnetic resonance imaging; activity = contrast enhancement of any lesion; inactivity = no contrast enhancement; n.d. = not determined; STER = intravenous (i.v.) corticosteroids; IFN = β interferon; GA = glatiramer acetate. Progression or improvement was considered when the EDSS scores, respectively, increased or decreased by 0·5 points when the initial score was ≥ 5.5 or by 1·0 or more points if the initial score was < 5·0, remaining unchanged for at least 3 months. Patients were treated with BCNU, Etoposide, AraC and Melphalan/horse anti‐human thymocyte globulin (BEAM/hATG) (BEAM group; patients 1–7) or cyclophosphamide/rabbit ATG (CY/rATG) (CY group; patients 8–18) conditioning regimens. Based on EDSS changes after autologous haematopoietic stem cell transplantation (AHSCT), from baseline to last visit, patients were classified, retrospectively, as: progression = patients who presented an increase in the EDSS scores; non‐progression = patients whose EDSS scores either decreased or remained stable.